TABLE 1.
In vitro activities of CEM-101 and other antimicrobials against Mycoplasma and Ureaplasma species isolated from humans
Organism (no. of isolates) and antimicrobial | MIC range (μg/ml) | MIC50 (μg/ml)a | MIC90 (μg/ml)a |
---|---|---|---|
M. pneumoniae (36) | |||
CEM-101 | ≤0.000000063-0.5 | 0.000032 | 0.000125 |
Azithromycin | ≤0.000016 to ≥32 | 0.00025 | 0.0005 |
Telithromycin | 0.000031 to ≥32 | 0.00025 | 0.001 |
Doxycycline | 0.016-0.25 | 0.125 | 0.25 |
Levofloxacin | 0.125-1 | 0.5 | 0.5 |
Linezolid | 32-128 | 64 | 128 |
M. genitalium (5) | |||
CEM-101 | ≤0.000032 | NA | NA |
Azithromycin | ≤0.000032-0.005 | NA | NA |
Telithromycin | ≤0.00003-0.00025 | NA | NA |
Doxycycline | ≤0.008-0.031 | NA | NA |
Levofloxacin | 0.125-1 | NA | NA |
Linezolid | 4-128 | NA | NA |
M. fermentans (15) | |||
CEM-101 | ≤0.008 | ≤0.008 | ≤0.008 |
Azithromycin | 0.125-1 | 0.5 | 0.5 |
Telithromycin | 0.002-0.031 | ≤0.008 | 0.016 |
Clindamycin | ≤0.008-0.063 | 0.016 | 0.031 |
Doxycycline | 0.016-0.5 | 0.125 | 0.5 |
Levofloxacin | ≤0.008-0.25 | 0.031 | 0.125 |
Linezolid | 0.5-4 | 1 | 4 |
M. hominis (13) | |||
CEM-101 | 0.002-0.008 | 0.004 | 0.008 |
Azithromycin | 0.5-4 | 4 | 2 |
Telithromycin | 0.125-0.5 | 0.25 | 0.5 |
Clindamycin | ≤0.008-0.031 | ≤0.008 | 0.016 |
Doxycycline | ≤0.008-0.016 | 0.125 | 8 |
Levofloxacin | 0.125-0.5 | 0.25 | 0.5 |
Linezolid | 1-8 | 2 | 4 |
U. parvum (10) | |||
CEM-101 | 0.002-0.031 | 0.008 | 0.016 |
Azithromycin | 0.5-4 | 2 | 4 |
Telithromycin | 0.008-0.063 | 0.063 | 0.125 |
Doxycycline | 0.031-16 | 8 | 16 |
Levofloxacin | 0.125-2 | 0.5 | 2 |
Linezolid | 128 to >256 | >256 | >256 |
U. urealyticum (10) | |||
CEM-101 | 0.004-0.063 | 0.008 | 0.031 |
Azithromycin | 0.5-4 | 2 | 4 |
Telithromycin | 0.016-0.25 | 0.063 | 0.25 |
Doxycycline | 0.031-32 | 1 | 16 |
Levofloxacin | 0.5-2 | 0.5 | 1 |
Linezolid | 256 to >256 | >256 | >256 |
NA, not applicable.